GILD · News · 20260918N
HIV PrEP Regulatory Expansion
GILEAD SCIENCES, INC. · 2026-09-18 · Importance 31 · Surprise 42 · In source text
Gilead entered an agreement with the Pan American Health Organization (PAHO) to expand access to lenacapavir in 14 Latin American and Caribbean countries. The twice-yearly HIV-prevention dosing is intended to improve adherence and address rising HIV incidence in the region. Lower pricing and the timing of regulatory adoption and procurement could constrain revenue and margins, although the agreement expands lenacapavir’s commercial reach.
Key facts
- Gilead Sciences recently expanded its HIV prevention licensing agreements to 120 high-incidence countries. source
- Gilead Sciences has entered an agreement with the Pan American Health Organization (PAHO) to expand access to its HIV-prevention drug lenacapavir in 14 Latin American and Caribbean countries. source
- Lenacapavir has a twice-yearly dosing advantage for adherence. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Gilead Sciences recently expanded its HIV prevention licensing agreements to 120 high-incidence countries. |
| revenue | positive | committed | — | Gilead Sciences has entered an agreement with the Pan American Health Organization (PAHO) to expand access to its HIV-prevention drug… |